NCT05382312View on ClinicalTrials.gov

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

May 27, 2025

Study Completion Date

May 27, 2025

Conditions
Tuberculosis
Interventions
DRUG

GSK3036656

GSK3036656 will be administered.

DRUG

Bedaquiline

Bedaquiline will be administered.

DRUG

Delamanid

Delamanid will be administered.

DRUG

RIFAFOUR e-275

RIFAFOUR e-275 will be administered.

DRUG

BTZ-043

BTZ-043 will be administered.

Trial Locations (1)

7530

GSK Investigational Site, Bellville

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Click-TB Consortium

UNKNOWN

lead

GlaxoSmithKline

INDUSTRY

NCT05382312 - Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis | Biotech Hunter | Biotech Hunter